Jump to content
  • Sign Up
  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
  • Posts

    • has anyone noticed something experiencing this unusual condition with them? First time I have seen something like this and the thing is erythema is extended to arms and the redness is not causing any pain and itchiness and the startling thing is I get intense erythema on my right cheek than my left cheek and  the erythema on my right hand is more than the left hand. So I was observing, has right face erythema anything to do with right hand erythema? Does it have any connection in common?
    • [Acne rosacea-a pedigree with ten cases]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Jul 10;36(7):747 Authors: Xia R, Cao L, Fang L, Xiong H, Yang L PMID: 31302927 [PubMed - in process] {url} = URL to article
    • Treatment of Rhinophyma With Surgical Excision and Amniotic Membrane. J Craniofac Surg. 2019 Jul;30(5):1563-1564 Authors: Yoo JJ, Thaller SR Abstract Rhinophyma is a phenotypic subtype of rosacea affecting the nose. It is characterized by phymatous changes, skin thickening/fibrosis, glandular hyperplasia, and chronic inflammation. Treatment of severe rhinophyma is predominantly surgical excision with closure by secondary intention. Amniotic membrane has been used to promote wound healing, fibrosis, and inflammation. In this case study, the authors present a 63-year-old male with longstanding rhinophyma treated with surgical excision with intraoperative placement of amniotic membrane. PMID: 31299768 [PubMed - in process] {url} = URL to article
    • Difference in Vasoconstrictors: Oxymetazoline vs Brimonidine. J Dermatolog Treat. 2019 Jul 11;:1-23 Authors: Okwundu N, Cline A, Feldman SR Abstract OBJECTIVE: Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. METHOD AND MATERIALS: Phase II and phase III clinical studies evaluating oxymetazoline and brimonidine were assessed to compare their efficacy and safety. RESULTS: In their respective phase III trials, both oxymetazoline and brimonidine met the primary efficacy outcome of having at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment and the Subject Self-Assessment Scales compared to the vehicle control. Treatment related adverse events of oxymetazoline and brimonidine are most often mild and localized. CONCLUSION: Topical oxymetazoline and brimonidine are effective for the management of persistent facial erythema associated with rosacea with a few mild and localized adverse effects. Further long term research is imperative to further understand their long term effects. PMID: 31294643 [PubMed - as supplied by publisher] {url} = URL to article
    • Acne and rosacea: What's new for treatment? Dermatol Ther. 2019 Jul 11;:e13020 Authors: Dursun R, Daye M, Durmaz K Abstract Acne and rosacea are two well-known chronic skin diseases in dermatology. There are many known therapeutic options of both diseases, but new treatment agents and therapeutic advances come to the agenda day by day. We would like to summarize new treatment advances for acne and rosacea diseases. This article is protected by copyright. All rights reserved. PMID: 31294907 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Case of lupus miliaris disseminatus faciei associated with marked formation of cysts, successfully treated with intralesional injections of triamcinolone acetonide. J Dermatol. 2017 Jul;44(7):e164-e165 Authors: Shimizu A, Funasaka Y, Ueno T, Kanzaki A, Saeki H PMID: 28342206 [PubMed - indexed for MEDLINE] {url} = URL to article
    • Noticed a couple of posts that nappy, [aka, diaper] (Australian English and British English), skin treatments are helpful in some cases. For example a post from Smacky at RF who reports, "I've been using Bepanthen for about a week now....So I tried Bepanthen, and within a few hours noticed the skin on my nose and cheeks had settled down a bit and looked better. I've been applying it every morning and night before bed, and every day this week I've woken up find my nose a little less red than the day before. I also haven't had a single new spot or lump. I woke up today and looked in the mirror and my nose is the same skin tone as my face. It's almost surreal. Its like looking at a different person who I'd forgotten about. I feel wonderful  Anyway I really hope this will help someone else." Ingredients in Bepanthen: Aqua, Lanolin, Paraffinum liquidum, Petrolatum, Panthenol, Prunus amygdalus dulcis oil, Cera alba, Cetyl alcohol, Stearyl alcohol, Ozokerite, Glyceryl oleate, Lanolin alcohol. Rubydo1 post no 2 states about this SD/Rosacea, "To be honest if it wasn’t for sudocrem I’d have a lot more spots." Sudocrem is a product made in Ireland which is available at Walmart. The ingredients for Sudocrem:  Zinc Oxide Ph. Eur., Benzyl Alcohol B.P., Benzyl Benzoate B.P., Benzyl Cinnamate, Lanolin, Purified Water, Liquid Paraffin, Paraffin wax, Beeswax, Micrcocrystalline wax, Sodium Benzoate, Linayl Acetate, Propylene Glycol, Citric Acid, Butylated Hydroxyanisole, Sorbitan Sesquioleate, Lavender fragrance  Ingredients for Dermocrem are similar:  A similar product that is also used to treat diaper rash is Rugby Zinc Oxide Ointment with the following ingredients:  Active ingredient Zinc oxide 20% Inactive ingredients mineral oil, petrolatum  
    • Gerd Plewig, MD, who volunteers on the RRDi MAC recently sent a message to all the RRDi members about his fourth edition of his classic book on acne and rosacea which we feature in our store. Below is his message:  On Mon, Jul 1, 2019 at 10:40 PM Plewig, Gerd Prof. Dr.med. wrote: Dear Members of the RRDi,   You may be interested that the  4th completely revised and augmented edition of Acne & Rosacea  is out. It is printed by Springer Milan, Italy, an can be ordered in print version, or electronically. The major chapter on rosacea has been  updated in text and  clinical illustrations. Also a new chapter on Demodex folliculorum mites with scanning electron microscopy images  is added. Finally a new chapter on the history of acne and rosacea is provided. Best wishes,   Gerd Plewig   Prof. Dr. Dr. h.c. mult. Gerd Plewig, FRCP Department of Dermatology University of Munich Frauenlobstrasse 9-11 80337 Munich Germany
    • Related Articles Nicotinic acid suppresses sebaceous lipogenesis of human sebocytes via activating hydroxycarboxylic acid receptor 2 (HCA2 ). J Cell Mol Med. 2019 Jul 05;: Authors: Markovics A, Tóth KF, Sós KE, Magi J, Gyöngyösi A, Benyó Z, Zouboulis CC, Bíró T, Oláh A Abstract Nicotinic acid (NA) activates hydroxycarboxylic acid receptor 2 (HCA2 ), and it is widely used in treating dyslipidaemias. Since its side effects include skin dryness, whereas its deficiency can be accompanied by dyssebacia, characterized by sebaceous gland enlargement, we asked if HCA2 is expressed on human sebocytes, and if NA influences sebocyte functions. By using human immortalized SZ95 sebocytes, we found that non-cytotoxic (≤100 μmol/L; MTT-assay) concentrations of NA had no effect on the homeostatic sebaceous lipogenesis (SLG; Nile Red), but normalized excessive, acne-mimicking SLG induced by several lipogenic agents (arachidonic acid, anandamide, linoleic acid + testosterone; Nile Red; 48-hr treatments). Moreover, it exerted significant anti-proliferative actions (CyQUANT-assay), and increased [Ca2+ ]IC (Fluo-4 AM-based Ca2+ -measurement). Although NA did not prevent the lipopolysaccharide-induced pro-inflammatory response (up-regulation [Q-PCR] and release [ELISA] of several pro-inflammatory cytokines) of the sebocytes, collectively, these data support the concept that NA may be effective in suppressing sebum production in vivo. While exploring the mechanism of the sebostatic actions, we found that sebocytes express HCA2 (Q-PCR, immunofluorescent labelling), siRNA-mediated silencing of which prevented the NA-induced Ca2+ -signal and the lipostatic action. Collectively, our data introduce NA, and HCA2 activators in general, as novel, potent and most likely safe sebostatic agents, with possible anti-acne potential. PMID: 31273921 [PubMed - as supplied by publisher] {url} = URL to article
    • Permethrin 5% Cream has also been found to improve demodectic rosacea. 
    • Queta at RF has posted her regimen for demodectic rosacea:  "Mix .5 TBL melted coconut oil (I put it in a the micro for a few seconds because it hardens at room temp) and 5-6 drop tea tree oil. Apply to face and leave on for 40 minutes each evening. I put some on my eyebrows and a little above my eyes but use extreme caution because tea tree oil will really burn your eyes if you get some in them. After waiting 40 minutes, wash off your face and do your usual nightly skin routine. For awhile after I was done washing my face I would use coconut oil as a moisturizer because I read that mites don't like it."
    • In the UK you can get a Rx from a doctor online at this website.  For example, you can get a Rx for Soolantra
    • It was announced by Galderma on its website on May 16, 2019, "Nestlé today announced that it has entered into exclusive negotiations with a consortium led by EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) for the sale of Nestlé Skin Health for a value of CHF 10.2 billion. The proposed transaction will be subject to employee consultations and approval of regulatory authorities and is expected to close in the second half of 2019."  
    • New evidence but still unmet medical needs in rosacea treatment. Br J Dermatol. 2019 Jul;181(1):11-12 Authors: Le Cleach L, Cribier B PMID: 31259410 [PubMed - in process] {url} = URL to article
    • The results of this study demonstrated that a single, high-density MFU-V treatment may be effective for treating erythematotelangiectatic rosacea. J Drugs Dermatol. 2019 Jun 01;18(6):522 Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea Schlessinger J, Lupin M, McDaniel D, George R
    • Related Articles A comment on Helicobacter pylori and rosacea. G Ital Dermatol Venereol. 2019 Aug;154(4):507-508 Authors: Sacco M PMID: 31251009 [PubMed - in process] {url} = URL to article
    • Related Articles What Is PFE? It May Just Be Time You Found Out.... J Drugs Dermatol. 2019 Jun 01;18(6):503 Authors: Del Rosso JQ Abstract With all the literature and research we have on acne and rosacea, there are still many unanswered questions. Over time, as we uncover more information on both preexisting and newly recognized pathophysiologic pathways, modes of drug action, alternative therapies, caveats related to basic skin care, and the potential roles for physical modalities, we often find that specific information that we thought was fact, is later altered, expanded, or corrected. What is interesting, and sometimes perplexing to me personally, is how difficult it is for the clinical dermatology community at large to incorporate well-published concepts into everyday clinical practice. PMID: 31251541 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles The Use of Oral Antibiotics in the Management of Rosacea J Drugs Dermatol. 2019 Jun 01;18(6):506 Authors: Nagler AR, Del Rosso J Abstract Rosacea is common inflammatory facial dermatosis. Rosacea has variable manifestations including facial flushing, central facial erythema, telangiectasias, and papulopustular lesions. Treatment of rosacea is challenging given the varied manifestations and incompletely understood etiology, but the treatment of papulopustular presentations often relies on oral antibiotics. Tetracyclines, specifically doxycycline, are the most commonly prescribed antibiotics for rosacea. Other antibiotics that can be used include macrolides, commonly azithromycin, and rarely, metronidazole. This paper will review the evidence for the use of antibiotics in the treatment of rosacea. J Drugs Dermatol. 2019;18(6):506-513. PMID: 31251542 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea J Drugs Dermatol. 2019 Jun 01;18(6):522 Authors: Schlessinger J, Lupin M, McDaniel D, George R Abstract Background: Anecdotal reports indicate the use of microfocused ultrasound with visualization (MFU-V) improves facial redness. Objective: The purpose of this pilot study was to assess the safety and effectiveness of MFU-V for improving the signs and symptoms of erythematotelangiectatic rosacea. Methods & Materials: Healthy adults with a clinical diagnosis of erythematotelangiectatic rosacea were enrolled (N=91). Eligible subjects had baseline Clinician Erythema Assessment (CEA) scores ≥3 and Patient Self-Assessment (PSA) of erythema scores ≥2. Subjects were randomized to receive one or two low-density MFU-V treatments or one or two high-density MFU-V treatments. Subjects were evaluated at 90, 180, and 365 days after treatment. The primary effectiveness endpoint was treatment success, defined as a 1-point change in CEA scores at 90 days post-treatment. Results: Across groups, 75 to 91.3% of subjects achieved treatment success at 90 days post-treatment. Notable adverse events include bruising (44%), tenderness/soreness (43%), and redness (35%). Treatment results were sustained, lasting up to 1 year. Subject satisfaction was high based on self-assessment questionnaires. Conclusion: The results of this study demonstrated that a single, high-density MFU-V treatment may be effective for treating erythematotelangiectatic rosacea. Based on these results, a large, randomized controlled study of single, high-density MFU-V treatment for erythematotelangiectatic rosacea is warranted. J Drugs Dermatol. 2019;18(6):522-531. PMID: 31251544 [PubMed - as supplied by publisher] {url} = URL to article
    • It really saddens us that Joanne Whitehead, Ph.D., has resigned from the board of directors of the RRDi. She was instrumental in obtaining and working with two educational grants we received from Galderma in 2015 and 2016. Her expertise will be missed and her volunteer spirit. The RRDi greatly appreciates all the volunteer work Dr. Whitehead performed for the RRDi. 
    • darren1 has shared his experience not only with YouTube but also with RF in this thread and you watch one of his videos below: 
    • Related Articles Contact allergy from fragrances and formaldehyde contributing to papulopustular rosacea. Contact Dermatitis. 2019 Jun 25;: Authors: Darrigade AS, Dendooven E, Aerts O Abstract Allergic contact dermatitis caused by fragrances and formaldehyde is common (1,2), but pustular dermatitis as a manifestation of contact allergy is rare (3). We report a case of therapy-resistant rosacea for which (occupational) contact allergy to fragrances, and to a lesser extent formaldehyde, was identified as an aggravating factor. This article is protected by copyright. All rights reserved. PMID: 31237351 [PubMed - as supplied by publisher] {url} = URL to article
    • Galderma has applied for a brimonidine foam patent which according to the patent is claimed to have the "advantage of remaining on the surface of the skin and of delivering a smaller amount so as to prevent undesirable effects (rebound effect) and too obtain a foam that is suitable for treating rosacea." US20190099369A1.pdf
    • And thats exactly the problem with Brevis. We have no way to check the levels of this parasite in rosacea. This study was able to check them by extracting eyelashes and found large numbers of brevis at the root. But what type of test is used to count them in the skin.  Surface tests will only count folliculorum levels and Soolantra won't have much of a problem killing them. But i have my doubts that it is able to kill brevis. 
    • Thanks Rory. Looking forward to your results. Did you see this paper about demodex brevis:  Demodex Brevis Higher Count Than Demodex Folliculorum in Cylindrical Dandruff Patients
    • Well, I think oral ivermectin should be more common as a rosacea treatment. Rosacea skin has a damaged barrier and topicals can be extremely difficult for many to tolerate. Also, topical treatments can be very slow to take effect as seen in a Galderma study of Soolantra where 30% of trial participants took up to a year to achieve clear/almost clear results. Then there is demodex brevis. A much smaller cousin of demodex folliculorum, which lives deeper in the pores. Little is known about brevis and, unlike folliculorum, it doesn't appear to exit pores at night to mate. If this is indeed the case then how do we kill it with a topical which may not penetrate the skin deep enough to reach it.  I think the horse paste is more of a hit in the States than in Europe. Its down to the crazy prescrition medication prices Americans pay, whereas in Europe Soolatra is many times cheaper. Ivermectin, as far as i know, is not water soluble. So any topical gel version of Soolantra will need one of those irritataing oil soluble excipients to disolve it. The horse paste looks like a gel but i have seen comments from people saying that it feels and looks like vaseline after applying it.  Anyway, I'll give it a couple of months and I'll post my results on the page you mentioned.
    • Actually I ran this by my dermatologist who was well aware that Rosaceans were using horse paste topically since he read about it in a journal. There are some dermatologists who are up to date with what is going on and then there are others who are in the dark. He told me that when prescribing Soolantra to his rosacea patients that about one in four patients were successful using it. He gave me a Rx for Soolantra and I tried it and I think now it was the inactive ingredients in Soolantra that irritated my skin. Galderma (or another pharmaceutical company) will probably eventually make an ivermectin gel with a very simple inactive ingredient list to compete with the horse paste that everyone is raving about. Galderma knows what is going on with rosaceans and obviously saw a slight dip in Soolantra sales due to thousands using horse paste. They know that a significant number of rosacea patients are not able to tolerate the inactive ingredients in Soolantra. 
    • Rory, thanks for clearing this up that you are taking the horse paste orally. We do have a thread dedicated to taking ivermectin orally. While many may think that taking oral ivermectin isn't a good idea, the fact is that oral ivermectin has been given to millions of people worldwide and there are long term studies on oral ivermectin in children. However, the RRDi recommends you check with your physician when embarking on this form of treatment as a precaution. It would be better you post in the oral ivermectin thread since this thread is about using horse paste topically. Thanks. 
    • The RRDi is pleased to announce that Apurva Tathe has been appointed to serve on the RRDi Board of Directors. She has a masters of science in biotechnology and is an excellent addition to the board. 
    • Related Articles Topical probiotics: the unknowns behind their rising popularity. Dermatol Online J. 2019 May 15;25(5): Authors: Lee GR, Maarouf M, Hendricks AJ, Lee DE, Shi VY Abstract OBJECTIVE: Topical probiotics have been used for skin care and treatment since the early 20th century. Over the past decade, there has been a dramatic surge of commercially-available topical probiotic products. We conducted a systematic search of clinical data relating to the use of topical probiotics and identified relevant clinical and regulatory gaps. METHODS: PubMed and Google Scholar searches were conducted for trials and reviews of probiotics. FDA definitions of cosmetics, drugs, and regulation of topical probiotics were reviewed. RESULTS: Topical probiotics have shown efficacy in a number of limited trials, particularly those involving the treatment of acne, atopic dermatitis, and rosacea. However, there is a paucity of literature on the safety profiles, mechanistic action, and therapeutic potential of topical probiotic products. Several regulatory gaps exist, including approval and classification of topical probiotic products by the FDA; currently there are no topical probiotic products the FDA has approved as drugs. CONCLUSION: With increasing popularity among the general public, but insufficient clinical data to demonstrate large-scale effectiveness and a thorough understanding of side effects, there is a need for further mechanistic and clinical investigation, as well as improved regulation and standardization of topical probiotic products. PMID: 31220895 [PubMed - in process] {url} = URL to article
    • Yes I'm ingesting it. I took a 250 lb dose. No, i dont weigh 250 lb. I just like the idea if a large dose. Each syringe has enough for a 1250 lb horse, so thats 5 doses per syringe. 
    • Ok I guess you are ingesting it orally? and if you are ingesting it orally, it has residual effects means it is stored in body fat and then progressively released to work and taking too often will cause build up. So you have mentioned that you have already taken your first dose so wait for one week and see the results and then follow the next dose and the recommended dose is 200 mcg(micrograms) per kilogram body weight but slight point difference will be ok but ask and consult your physician before you take any treatment.
    • What I mean is, you are using the Bimectin topically, correct? 
    • No, its the oral, apple flavoured horse paste with the syringe. You have a picture of it at the top of this page. The ingredients are not listed on the box. 
    • The Bimectin is topical, correct? Does it list the inactive ingredients?
    • Item 109 – UE 4 Dermatoses faciales : acné, rosacée, dermatite séborrhéique. Ann Dermatol Venereol. 2018 Mar;145 Suppl 1:S7-S16 Authors: CEDEF PMID: 29429583 [PubMed - indexed for MEDLINE] {url} = URL to article
    • I ordered Bimectin Brady. It arrived 2 days ago. Not easy to get cause its not available in some european countries. I took a dose yesterday on an empty stomach with plenty of water. Not exactly sure when i should take the next dose, maybe in a few days or next week. So, all i can do now is wait and see what happens.
    • [PATHOGENETIC FEATURES AND METHODS FOR TREATMENT OF VARIOUS FORMS OF ROSACEA]. Georgian Med News. 2019 Apr;(289):116-120 Authors: Tsiskarishvili T, Katsitadze A, Tsiskarishvili NV, Tsiskarishvili NI, Chitanava L Abstract The aim of the work was to study the features of the pathogenesis of various clinical forms of rosacea (the presence of mite Demodex folliculorum, the determination of VEGF, IL-2 IL-6, IL-8) and, based on the obtained results, to ensure adequate methods of therapy. Mite identification was performed by microscopy. The concentration of cytokines in patients with various clinical forms of rosacea (papulopustular form 15 patients, steroid form - 15, erythematous telangiectic form - 10, Ophthalmo Rosacea - 3, rhinophyma - 3) was determined by enzyme immunoassay using appropriate monoclonal antibodies and expressed in samples. Based on the results we obtained in the local treatment of patients with papulopustular rosacea (with a high population density of demodicosis ticks and an increased concentration of IL-8 in the blood), 1% ivermectin cream was applied externally to the skin of the face 1 time per day every day for the entire course of treatment (3-4 months). In patients with erythematous-teloangiectatic form (with a high cytokine VEGF, IL-8), a combined phased use of 1% pimecrolimus cream 14 days and 0.5% bromonidine tartrate gel was administered once a day - 14 days (with a single course of 1 month). In patients with a steroid form of rosacea with a high concentration of cytokines (IL-2, IL-6, IL-8), 1% pimecrolimus was administered 2 times a day - 1 month, 1% ivermectin 1 time a day - 14 days. During therapy, patients with advanced treatment were divided into 2 groups. Patients of group 1, who received externally 1% ivermectin 1 time per day as the main therapy, in the evening for 16 weeks. Group 2 applied 1% ivermectin and 1% pimercolimus cream for 16 weeks. In group 2 patients showed a significant improvement in a shorter time (4 weeks compared to 8 weeks in 1 group of patients). Taking into account the torpid flow and the difficulty of rosacea therapy, the pathogenetic approach when choosing new external preparations, opens promising directions for further deeper study of the pathophysiological mechanisms underlying the individual clinical forms of dermatosis. At the same time, the efficacy and safety of using ivermectin, pimecrolimus, and brimonidine tartrate in the treatment of various forms of this dermatosis suggests their widespread use in practical dermatology. PMID: 31215891 [PubMed - in process] {url} = URL to article
    • We have some instructions provided by IPS on how to use our forum. For example, watch this video on how to change your display name:  Editing your profile Sending/Receiving messages General Posting Control Previewing post content Managing followed content How to Use CLUBS Two Factor Authentication Viewing Attachments Reputation & Reactions Custom Profile Fields User Ranks Post color highlighting Profile Completion Other Profile Settings
    • "The mechanism of action (MOA) of Soolantra® (ivermectin) Cream, 1% in treating rosacea lesions is unknown." However, we are concentrating on an investigation into the 'basis for the vehicle' statement by Galderma regarding Soolantra.  In the Soolantra News post if you scroll down to Cetaphil Base, Galderma, on its Mechanism of Action page, posts : "Soolantra Cream combats inflammatory lesions of rosacea with a formulation designed for tolerability, utilizing Cetaphil® Moisturizing Cream as the basis for the vehicle." However, now this page is no longer available, but we have a screen shot of the Way Back Machine on August 21, 2018 which shows you the statement below:  Soolantra mechanism of action (MOA) (Way Back Machine url)  Actually after a careful search, Galderma has moved the statement that Cetaphil is the 'basis for the vehicle' statement to this page:  https://www.soolantra.com/hcp/about-soolantra-cream SOOLANTRA (ivermectin) cream, 1% is a white to pale yellow hydrophilic cream. Each gram of SOOLANTRA cream contains 10 mg of ivermectin. It is intended for topical use. While the claim by Galderma that utilizing Cetaphil is 'basis for the vehicle' we have investigated and notice the differences with the inactive ingredients in Soolantra with the ingredients in Cetaphil below.  SOOLANTRA cream contains the following inactive ingredients: carbomer copolymer type B, cetyl alcohol, citric acid monohydrate, dimethicone, edetate disodium, glycerin, isopropyl palmitate, methylparaben, oleyl alcohol, phenoxyethanol, polyoxyl 20 cetostearyl ether, propylene glycol, propylparaben, purified water, sodium hydroxide, sorbitan monostearate, and stearyl alcohol. Source Cetaphil Moisturizing Cream Ingredients: Water, Glycerin, Petrolatum, Dicaprylyl Ether, Dimethicone, Glyceryl Stearate, Cetyl Alcohol, Prunus Amygdalus Dulcis (Sweet Almond) Oil, PEG-30 Stearate, Tocopheryl Acetate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Dimethiconol, Benzyl Alcohol, Phenoxyethanol, Glyceryl Acrylate/Acrylic Acid Copolymer, Propylene Glycol, Disodium EDTA, Sodium Hydroxide Source Compare Soolantra inactive ingredients to Cetaphil Moisturizing Cream Ingredients Google Sheet
  • Latest Products

    • Dirty Looks: The Secret to Beautiful Skin

      $11.59 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

    • Dermocrem

      $17.99 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

    • Lactacyd Derma Gel Liquid Soap

      $33.28 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

    • Swanson NAC N-Acetyl Cysteine

      $8.37 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

    • Plewig and Kligman´s Acne and Rosacea 4th ed. 2019 Edition

      $234.90 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

  • Create New...